PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

被引：221

作者：

Carpinelli, Patrizia ^{[1
]}

Ceruti, Roberta ^{[1
]}

Giorgini, Maria Laura ^{[1
]}

Cappella, Paolo ^{[1
]}

Gianellini, Laura ^{[1
]}

Croci, Valter ^{[1
]}

Degrassi, Anna ^{[1
]}

Texido, Gernma ^{[1
]}

Rocchetti, Maurizio ^{[1
]}

Vianello, Paola ^{[1
]}

Rusconi, Luisa ^{[1
]}

Storici, Paola ^{[1
]}

Zugnoni, Paola ^{[1
]}

Arrigoni, Claudio ^{[1
]}

Soncini, Chiara ^{[1
]}

Alli, Cristina ^{[1
]}

Patton, Veronica ^{[1
]}

Marsiglio, Aurelio ^{[1
]}

Ballinari, Dario ^{[1
]}

Pesenti, Enrico ^{[1
]}

Fancelli, Daniele ^{[1
]}

Moll, Jurgen ^{[1
]}

机构：

[1] Nerviano Med Sci SRI Oncol, I-20014 Milan, Italy

来源：

MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期

关键词：

D O I：

10.1158/1535-7163.MCT-07-0444

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PHA-739358 is a small-molecule 3-aminopyrazole derivative with strong activity against Aurora kinases and cross-reactivities with some receptor tyrosine kinases relevant for cancer. PHA-739358 inhibits all Aurora kinase family members and shows a dominant Aurora B kinase inhibition related cellular phenotype and mechanism of action in cells in vitro and in vivo. p53 status-dependent endoreduplication is observed upon treatment of cells with PHA-739358, and phosphorylation of histone H3 in Ser(10) is inhibited. The compound has significant antitumor activity in different xenografts and spontaneous and transgenic animal tumor models and shows a favorable pharmacokinetic and safety profile. In vivo target modulation is observed as assessed by the inhibition of the phosphorylation of histone H3, which has been validated preclinically as a candidate biomarker for the clinical phase. Pharmacokinetics/pharmacodynamics modeling was used to define drug potency and to support the prediction of active clinical doses and schedules. We conclude that PHA-739358, which is currently tested in clinical trials, has great therapeutic potential in anticancer therapy in a wide range of cancers.

引用

页码：3158 / 3168

页数：11

共 49 条

[11]

Dagher R, 2002, CLIN CANCER RES, V8, P3034

[12] Multiple targeted tyrosine kinase inhibition in the clinic: All for one or one for all? [J].

de Jonge, M. J. A. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (10) :1351-1356

[13] Magnetic resonance imaging and histopathological characterization of prostate tumors in TRAMP mice as model for pre-clinical trials [J].

Degrassi, Anna ;

Russo, Micaela ;

Scanziani, Eugenio ;

Giusti, Anna ;

Ceruti, Roberta ;

Texido, Gernma ;

Pesenti, Enrico .

PROSTATE, 2007, 67 (04) :396-404

[14] Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores [J].

Ditchfield, C ;

Johnson, VL ;

Tighe, A ;

Ellston, R ;

Haworth, C ;

Johnson, T ;

Mortlock, A ;

Keen, N ;

Taylor, SS .

JOURNAL OF CELL BIOLOGY, 2003, 161 (02) :267-280

[15] Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene:: a meta-analysis of multiple cancer types [J].

Ewart-Toland, A ;

Dai, Q ;

Gao, YT ;

Nagase, H ;

Dunlop, MG ;

Farrington, SM ;

Barnetson, RA ;

Anton-Culver, H ;

Peel, D ;

Ziogas, A ;

Lin, DX ;

Miao, XP ;

Sun, T ;

Ostrander, EA ;

Stanford, JL ;

Langlois, M ;

Chan, JM ;

Yuan, JW ;

Harris, CC ;

Bowman, ED ;

Clayman, GL ;

Lippman, SM ;

Lee, JJ ;

Zheng, W ;

Balmain, A .

CARCINOGENESIS, 2005, 26 (08) :1368-1373

[16] Potent and selective aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition [J].

Fancelli, D ;

Berta, D ;

Bindi, S ;

Cameron, A ;

Cappella, P ;

Carpinelli, P ;

Catana, C ;

Forte, B ;

Giordano, P ;

Giorgini, ML ;

Mantegani, S ;

Marsiglio, A ;

Meroni, M ;

Moll, J ;

Pittalà, V ;

Roletto, F ;

Severino, D ;

Soncini, C ;

Storici, P ;

Tonani, R ;

Varasi, M ;

Vulpetti, A ;

Vianello, P .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (08) :3080-3084

[17] 1,4,5,6-tetrahydropyrrolo[3,4-c] pyrazoles:: Identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile [J].

Fancelli, Daniele ;

Moll, Jurgen ;

Varasi, Mario ;

Bravo, Rodrigo ;

Artico, Roberta ;

Berta, Daniela ;

Bindi, Simona ;

Cameron, Alexander ;

Candiani, Ilaria ;

Cappella, Paolo ;

Carpinelli, Patrizia ;

Croci, Walter ;

Forte, Barbara ;

Giorgini, Maria Laura ;

Klapwijk, Jan ;

Marsiglio, Aurelio ;

Pesenti, Enrico ;

Rocchetti, Maurizio ;

Roletto, Fulvia ;

Severino, Dino ;

Soncini, Chiara ;

Storici, Paola ;

Tonani, Roberto ;

Zugnoni, Paola ;

Vianello, Paola .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (24) :7247-7251

[18] A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease [J].

Fiedler, W ;

Serve, H ;

Döhner, H ;

Schwittay, M ;

Ottmann, OG ;

O'Farrell, AM ;

Bello, CL ;

Allred, R ;

Manning, WC ;

Cherrington, JM ;

Louie, SG ;

Hong, W ;

Brega, NM ;

Massimini, G ;

Scigalla, P ;

Berdel, WE ;

Hossfeld, DK .

BLOOD, 2005, 105 (03) :986-993

[19] MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation [J].

Giles, Francis J. ;

Cortes, Jorge ;

Jones, Dan ;

Bergstrom, Donald ;

Kantarjian, Hagop ;

Freedman, Steven J. .

BLOOD, 2007, 109 (02) :500-502

[20] The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function [J].

Gizatullin, Farid ;

Yao, Yao ;

Kung, Victor ;

Harding, Matthew W. ;

Loda, Massimo ;

Shapiro, Geoffrey I. .

CANCER RESEARCH, 2006, 66 (15) :7668-7677

← 1 2 3 4 5 →